Dr. Clay Siegall is an acclaimed scientist, academician, entrepreneur, and a respected author. He is the Co-founder, CEO and the Chairman of the Board of Seattle Genetics. His company specializes in the development of therapy options and drugs for critical diseases like cancer. Due to his exceptional skills, Seattle Genetic is currently ranked among the top companies in the field of cancer therapy. The company is credited with coming up with a robust series of more than 20 drugs that revolutionized the treatment of various types of cancer.
Seattle Genetics has evolved from a tiny start-up to a giant reckon with. More companies are partnering with Seattle Genetics with the aim of finding solutions to the world’s most dreaded deceases. For instance, Seattle Genetics partnered with Takeda Pharmaceutical Company to come up the first ADC product, ADCETRIS. The drug became an instant success and is now a global brand that has attained approval requirements of more than 65 countries.
Despite Seattle Genetics’ unending successes, Dr. Clay Siegall still strives to enhance its ADC technology. His relentless efforts have seen Seattle Genetics sign multiple strategic licenses and agreements for its ADC innovation. To date, the strategic licenses have generated more than $350 million. Dr. Clay Siegall has also led his company into successful capital-raising activities and secured more than a billion through public and private financing.
Before he founded the famous Seattle Genetics, Siegall served at the National Cancer Institute from 1988 to 1991. He moved on to work for Bristol-Myers Squibb Pharmaceutical Research Institute before he established Seattle Genetics. Siegel is a Director of the Board governing Ultragenyx Pharmaceutical and Washington Roundtable. The exceptional scientist is also a recipient of many awards. For example, he secured the Pacific Northwest Ernst & Young Entrepreneur of the Year back in 2012. The knowledgeable scientist has also authored many publications.
Siegall received his Ph.D. from George University and B.S in Zoology from the University of Maryland. He appreciates the fact that you cannot succeed alone. For this reason, he accentuates on the need to associate with smart people and learn from them. He also advocates for innovations and encourages the use of innovative technologies in the oncology drug development.